Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

21st Century Cures Implementation: Device Provision Updates

Executive Summary

Dozens of reforms impacting the medtech sector were signed into law Dec. 13, 2016, in the 21st Century Cures Act. Here's a breakdown of where things stand in the implementation of key provisions.

You may also be interested in...



President Calls For Almost $100M More In Funding For FDA Device Activities In 2020

The current administration would use an additional $98m in congressional budget authority in the 2020 fiscal year for FDA’s medical device efforts to modernize its regulatory approach for technology development, to enable device safety issues to be monitored more closely, and to advance new approaches for regulating digital health technologies and breakthrough devices.

Devices Addressed In US FDA's New Regenerative Medicine Framework

The framework includes two draft guidance documents and two final guidances. One of the drafts, which focuses on the regulation of devices used with regenerative medicine, implements a provision of the 21st Century Cures Act and strongly suggests that most of these products will be regulated via class II.

AdvaMed CEO Supports Potential HHS Secretary Nominee Azar

AdvaMed CEO Scott Whitaker says Alex Azar, who is reportedly the top candidate to be nominee for US Health and Human Services secretary, would be ideal for the job with his extensive experience at the department.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel